DLL3
Overview
DLL3 (Delta-like ligand 3) is a Notch pathway ligand that acts as an inhibitory regulator of Notch signaling. It is expressed on the surface of neuroendocrine tumor cells but not on normal adult tissues, making it an attractive therapeutic target in neuroendocrine neoplasms. DLL3 high expression has been used as a biomarker to guide DLL3-targeted therapies including antibody-drug conjugates and T-cell engagers.
Alterations observed in the corpus
- High DLL3 expression supported DLL3-inhibitor therapeutic recommendations in neuroendocrine neoplasm patients PN11, PN19, and PN22 in a precision oncology cohort PMID:24326773
Cancer types (linked)
- Neuroendocrine neoplasms (PanNENs, PulNENs, ovarian MiNEN): high DLL3 expression observed and used as a therapeutic biomarker PMID:24326773
Co-occurrence and mutual exclusivity
Therapeutic relevance
- DLL3-targeted therapy (DLL3 inhibitors) recommended in NEN patients with high DLL3 expression PMID:24326773
Open questions
Sources
This page was processed by entity-page-writer on 2026-05-09.